Black Diamond Therapeutics
BDTX
102 hedge funds and large institutions have $308M invested in Black Diamond Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 13 reducing their positions, and 35 closing their positions.
215% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 13
10% less funds holding
Funds holding: 113 → 102 (-11)
10.55% less ownership
Funds ownership: 80.79% → 70.24% (-11%)
31% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 35
33% less call options, than puts
Call options by funds: $946K | Put options by funds: $1.42M
56% less capital invested
Capital invested by funds: $705M → $308M (-$397M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$24.1M |
| 2 |
Morgan Stanley
New York
|
+$11.6M |
| 3 |
Two Sigma Investments
New York
|
+$5.76M |
| 4 |
SG Americas Securities
New York
|
+$5.45M |
| 5 |
BlackRock
New York
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$28.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$13.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$13M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.3M |
BDTX Hedge Fund Activity: Q2 2021 in Review
102 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2021, worth a combined $308M — down 56% from $705M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of BDTX and 24 opened new positions — a net loss of 11 holders — while 13 trimmed existing stakes and 41 added.
The largest buyer was Bellevue Group, adding an estimated $24.1M. The largest seller was Fidelity Investments, cutting an estimated $34.2M.
- 102 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2021, down from 113 in Q1 2021.
- Funds reported $308M of Black Diamond Therapeutics stock for Q2 2021, down 56% quarter-over-quarter.
- 24 funds opened new Black Diamond Therapeutics positions in Q2 2021 and 35 closed out, a net change of -11 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2021 was Bellevue Group, an estimated $24.1M added.
- The largest Black Diamond Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $34.2M sold.
Based on aggregated 13F filings for Q2 2021.